CytRx Corporation (CYTR): Price Target and June Short Interest Disclosure

CytRx Corporation (CYTR) : Average target price received by CytRx Corporation (CYTR) is $4.58 with an expected standard deviation of $4.82. The most aggressive target on the stock is $10, whereas the most downbeat target is $1. 3 financial analysts are currently covering the stock.

CytRx Corporation (CYTR) has seen a rise of 92,164 shares or 0.7% in the short interest. The remaining shorts are 24.5% of the total floated shares. The net short interest, as on June 30,2016, stood at 14,213,235 shares and the stocks days to cover will be 20 by factoring in the average per day volume of 713,681 shares. On June 15,2016, 14,121,071 shares were shorted. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.


CytRx Corporation (NASDAQ:CYTR): On Thursdays trading session , Opening price of the stock was $0.98 with an intraday high of $0.98. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.85. However, the stock managed to close at $0.899, a loss of 8.27% for the day. On the previous day, the stock had closed at $0.9801. The total traded volume of the day was 7,186,273 shares.

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is focused on the clinical development of aldoxorubicin, its modified version of a chemotherapeutic agent. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. It consists of (6-Maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Its laboratory in Freiburg, Germany is conducting discovery and translational research to create drug candidates that utilize linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.